Exploratory analyses of efficacy data from schizophrenia trials in support of new drug applications submitted to the US Food and Drug Administration.
about
Bypassing P-Glycoprotein Drug Efflux Mechanisms: Possible Applications in Pharmacoresistant Schizophrenia TherapyMedication Nonadherence, "Professional Subjects," and Apparent Placebo Responders: Overlapping Challenges for Medications DevelopmentRegulatory and scientific issues regarding use of foreign data in support of new drug applications in the United States: an FDA perspective.A regulatory perspective on missing data in the aftermath of the NRC report.Comparative efficacy and safety of antipsychotics in the treatment of schizophrenia: a network meta-analysis in a Japanese population.A Double-Blind, Placebo-Controlled Comparator Study of LY2140023 monohydrate in patients with schizophreniaA double-blind, placebo-controlled, randomized withdrawal study of lurasidone for the maintenance of efficacy in patients with schizophrenia.Cariprazine in the treatment of schizophrenia: a proof-of-concept trialCNS sites cooperate to detect duplicate subjects with a clinical trial subject registry.Dose equivalents for second-generation antipsychotics: the minimum effective dose method.Modelling and simulation of placebo effect: application to drug development in schizophrenia.Onset and persistence of efficacy by symptom domain with long-acting injectable paliperidone palmitate in patients with schizophrenia.Survey of antipsychotic medication curriculum content in Australian university nursing programmes.Remarks on designs enriching for placebo non-responders.Does long term use of psychiatric drugs cause more harm than good?A sequential enriched design for target patient population in psychiatric clinical trials.Development of a placebo effect model combined with a dropout model for bipolar disorder.The plan of enrichment designs for dealing with high placebo response.
P2860
Q26780502-6D9D6F6C-8D7E-428C-AD20-6091134C1FF8Q28088434-DAAF1276-DA70-4D54-8C3E-A648185E86BCQ30616911-42F96AD4-B193-4377-A296-518FF568A6A4Q31032578-89193AD8-5B98-460E-95EE-F7EBADB2768AQ33713759-BCED21AB-3F19-4A08-9B73-D5BC71770CF4Q34770351-48824370-3E4E-4B7D-8BF2-681C8F3A30F6Q36475355-0002D9D8-0019-4435-A81F-662B46D5840CQ36530048-7E4DCFF5-CC44-4376-AE9B-CA65B3616BECQ36737423-31AA37BE-016C-410E-963F-0F13EAEAF4F4Q37598284-4D3EA129-0991-4A6C-A202-8E3B59994B04Q38073697-D74C0524-BDB6-4845-AD3F-9E8A87409064Q38206231-8C642127-EEE5-49D3-A52C-49DA1AB3D475Q39159979-A7EABA6D-E4FC-45EB-A45B-AE8278A3433FQ40107082-E60E30B6-0F15-47FE-A8FB-5B3419204C6EQ40928053-22D9CD90-FBE9-4A3E-9B1C-DE15B6F93D91Q40994749-45518844-6DB5-4135-8AC0-D97003380346Q43480141-6B1D7D6D-67FF-49F7-9907-6C48A3BFE4ABQ48377645-10D0E0D8-72EB-493B-B122-4EDB2A7F1110
P2860
Exploratory analyses of efficacy data from schizophrenia trials in support of new drug applications submitted to the US Food and Drug Administration.
description
2012 nî lūn-bûn
@nan
2012 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2012 թվականի մայիսին հրատարակված գիտական հոդված
@hy
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
name
Exploratory analyses of effica ...... Food and Drug Administration.
@ast
Exploratory analyses of effica ...... Food and Drug Administration.
@en
Exploratory analyses of effica ...... Food and Drug Administration.
@nl
type
label
Exploratory analyses of effica ...... Food and Drug Administration.
@ast
Exploratory analyses of effica ...... Food and Drug Administration.
@en
Exploratory analyses of effica ...... Food and Drug Administration.
@nl
prefLabel
Exploratory analyses of effica ...... Food and Drug Administration.
@ast
Exploratory analyses of effica ...... Food and Drug Administration.
@en
Exploratory analyses of effica ...... Food and Drug Administration.
@nl
P2093
P356
P1476
Exploratory analyses of effica ...... Food and Drug Administration.
@en
P2093
Peiling Yang
Thomas P Laughren
Yeh-Fong Chen
P304
P356
10.4088/JCP.11R07539
P577
2012-05-15T00:00:00Z